Clinical trials: Genital Neoplasm, Female
Infections, Papillomavirus, Papillomavirus Vaccines
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This Phase IV, observer-blind study is designed to evaluate the safety and immunogenicity of Cervarix in HIV infected…
- Trial name
- NCT01031069
- Testing
- GSK Biologicals' HPV vaccine 580299, Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
- Where
- 15 sites in Brazil, Estonia and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Uterine Fibroids, Heavy Menstrual Bleeding
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
This is an extension study for women who have already received six months of treatment in the phase III clinical trial M12-815 (NCT02654054) or M12-817 (NCT02691494), and will evaluate the long-term efficacy and safety of…
- Trial name
- NCT02925494
- Testing
- Estradiol/Norethindrone Acetate, Elagolix
- Where
- 124 sites in United States, Canada and 1 more
- Volunteers
- 433 people
- Sponsor
- AbbVie
Esophageal Cancer, Lung Cancer
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens.
- Conditions
- Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer
- Trial name
- NCT00291473
- Testing
- CHP-HER2, CHP-NY-ESO-1
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Ovarian Cancer
IM-862 in Treating Patients With Recurrent Ovarian Cancer
RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of IM-862 in treating patients who have recurrent ovarian cancer after treatment with…
- Trial name
- NCT00003773
- Testing
- oglufanide disodium
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Southern California
Solid Tumor, Advanced Solid Tumor
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor, Colon Rectal Cancer
- Trial name
- POPCORN (NCT06028724)
- Where
- Italy
- Volunteers
- 782 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Ovary Cancer
The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women
This is a Prospective, Self-Controlled, Open-Label, Multicenter Clinical Trial. The purpose of this study is to demonstrate the efficacy and safety of FRD001 injection in ultrasound contrast imaging for the differentiation…
- Trial name
- NCT06556342
- Testing
- FRD001
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Tongji Hospital
Solid Tumors, Ovarian Cancer
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201. Part 1 will be a dose-escalation study.
- Trial name
- NCT03427073
- Testing
- ALM201
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Almac Discovery
Uterine Cervical Dysplasia
Trial on Safety and Pharmacokinetics of Intravaginal Curcumin
The main objective of this study is to determine the maximum tolerable dose and safety of intravaginal curcumin in a normal population of women (women with no evidence of cervical cytological abnormalities by pap testing).
- Trial name
- NCT01035580
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Emory University
Infections, Papillomavirus
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK
This study will assess the risk of spontaneous abortion during weeks 1-23 and weeks 1-19 of gestation, respectively, and other pregnancy outcomes, in an exposed cohort, i.e.
- Trial name
- NCT01905462
- Testing
- Data Collection, Cervarix
- Where
- United Kingdom
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Empowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM
An Individualised and Patient-centred Follow-up Program for Women With Gynaecological Cancer
This randomized controlled trial is testing the hypothesis that an individually focused and need-based nurse led follow-up program supported by electronic Patient Reported Outcome Measures for women with gynecological cancer will…
- Trial name
- NEMO (NCT03838861)
- Testing
- NEMO: NEw MOdel of follow-up
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- University of Southern Denmark
Solid Tumor, Adult
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018).
- Trial name
- NCT05230186
- Testing
- Tumor Biopsy
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- TScan Therapeutics, Inc.
Polycystic Ovarian Syndrome (PCOS), Infertility
Effect of NAE on Polycystic Ovarian Syndrome (PCOS)
Polycystic Ovarian Syndrome (PCOS) is a multifaceted endocrine metabolic condition impacting about 5-10% of women throughout their reproductive lifespan.
- Conditions
- Polycystic Ovarian Syndrome (PCOS), Infertility, Metabolic Disorders
- Trial name
- NAE-PCOS (NCT07603505)
- Testing
- Herbal Formulation, Metformin XR, Metformin 750 mg and herbal formulation 500 mg
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- Jinnah Sindh Medical University
Cervical Intraepithelial Neoplasia, Uterine Artery Hemodynamics
Changes in Uterine Artery Resistance Index Following Cervical Conization
The objective of this prospective study is to evaluate the hemodynamic impact of cervical conization on uterine artery blood flow by focusing on the Resistance Index (RI) as a direct indicator of distal vascular resistance.
- Trial name
- NCT07653191
- Testing
- Cervical Conization
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Adana City Training and Research Hospital
Ovarian Clear Cell Carcinoma, Endometrial Cancer
TR115 in ARID1A-Mutated Advanced Solid Tumors
This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.
- Conditions
- Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
- Trial name
- NCT07793318
- Testing
- TR115
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- SORAYA (NCT04296890)
- Testing
- Mirvetuximab Soravtansine
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- ImmunoGen, Inc.
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
Insulin Resistance, Oxidative Stress
Alpha Lipoic Acid and Polycystic Ovary Syndrome
The study will recruit 40 subjects with Polycystic Ovary Syndrome (PCOS) as defined by the NIH criteria. The subjects will be pre-screened for insulin sensitivity using fasting insulin and glucose levels and oral glucose…
- Trial name
- NCT00505427
- Testing
- Alpha Lipoic Acid
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Francisco
Ovarian Cancer, Fallopian Tube Cancer
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer
This is an open-label, pilot study in patients with a diagnosis of recurrent ovarian, fallopian tube or primary peritoneal carcinoma who have undergone standard cytoreductive surgery following by adjuvant chemotherapy.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- NCT01144442
- Testing
- Hyperthermic intraperitoneal chemotherapy with Carboplatin, Isotonic saline (perfusate), Surgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cervical Intraepithelial Neoplasia
TMTP1-ICG Mapping in Colposcopy-directed Biopsy
Investigators aimed to determine the validity of the novel tumor targeted fluorescent TMTP1-ICG to increased accuracy of colposcopy-directed biopsy.
- Trial name
- NCT03321461
- Testing
- TMTP1, ICG
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huazhong University of Science and Technology
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.